A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer

BACKGROUND: The mammalian target of rapamycin (mTOR) pathway is deregulated in castration-resistant prostate cancer (CRPC). We investigated the efficacy and toxicity of temsirolimus, an mTOR inhibitor, in chemotherapy-naïve CRPC. METHODS: In this phase II open label study, eligible patients received...

Descripción completa

Detalles Bibliográficos
Autores principales: Kruczek, K, Ratterman, M, Tolzien, K, Sulo, S, Lestingi, T M, Nabhan, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790181/
https://www.ncbi.nlm.nih.gov/pubmed/24008662
http://dx.doi.org/10.1038/bjc.2013.530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790181/
https://www.ncbi.nlm.nih.gov/pubmed/24008662
http://dx.doi.org/10.1038/bjc.2013.530

Ejemplares similares